epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-118, Phase II. In start-up

Treatment-resistant major depressive disorder

FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.

Every risk that applies to this study, scored after TransCelerate's risk assessment tool. The KRIs and QTLs tabs set out what watches each one.

This study carries 45 risks

They come from its protocol answers, its countries and the kinds of site it uses: nine score high and 16 medium. Of those, 16 are not yet watched by any KRI, KPI or QTL. A new KRI or a closer look there would lower the risk most.

ScoreRiskWhy it applies hereL×I×DWatched by
18HighPlacebo or no-added-treatment control armPD-05, evidence grade B; design riskWhat does the control arm receive? Placebo or no added treatment3×3×2QTL: stopped study treatment early
18HighCompeting trials for the same patientsEB-02, evidence grade A; design riskHow many competing trials recruit the same patients? Many, and the eligible pool is small3×2×3Nothing yet
18HighActive comparator (against placebo) in registry dataPD-17, evidence grade B; design riskWhat does the control arm receive? Placebo or no added treatment3×2×3Nothing yet
18HighAcademic and hospital sites, and sites new to the sponsor, take longer to activatePM-02, evidence grade B; design riskHave most sites worked with the sponsor before? No, mostly new sites3×2×3Nothing yet
18HighFragmented, negotiated costing and contractingPOL-03, evidence grade A; country riskUnited Kingdom: Costing and contracting were the longest start-up step; the national contract has shortened it · Spain: Site contracts took 117 days in 2016 and about 90 after national templates3×2×3Nothing yet
18HighEthics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness)POL-20, evidence grade B; country riskPoland: A central ethics committee reviews every study; its effect on timelines is not measured3×2×3Nothing yet
18HighInvestigator attrition and one-and-done investigatorsS-08, evidence grade C; site riskCommunity hospital: 8% of sites · Site new to research: 45% of sites3×2×3Nothing yet
18HighCompeting trialsS-21, evidence grade B; design and site riskHow many competing trials recruit the same patients? Many, and the eligible pool is small · Academic medical centre: 8% of sites · Dedicated research centre: 18% of sites3×2×3Nothing yet
18HighCompeting trials at a siteSH-30, evidence grade D; design riskHow many competing trials recruit the same patients? Many, and the eligible pool is small3×2×3Nothing yet
12MediumFollow-up burden and durationEB-17, evidence grade C; design riskHow heavy is the visit and procedure schedule? Heavier than typical2×3×2QTL: missing primary endpoint data; QTL: lost to follow-up or withdrew consent
12MediumComorbidity exclusionsPD-15, evidence grade B; design riskDoes the protocol exclude common comorbidities? Yes2×3×2QTL: ineligible patients randomised
12MediumOverestimated eligible pool (Lasagna's law)EB-01, evidence grade B; design riskHow many non-essential exclusions does the protocol carry? Three or more3×2×2Study KPIs
12MediumBlinded placebo-controlled design instead of open-labelEB-03, evidence grade A; design riskIs the study blinded? Blinded2×2×3Nothing yet
12MediumOlder adults under-enrolledPB-10, evidence grade A; design riskIs there an upper age limit? Yes2×2×3Nothing yet
12MediumBlinded placebo-controlled against open designPD-06, evidence grade A; design riskIs the study blinded? Blinded2×2×3Nothing yet
12MediumWashout periods and concomitant-medication exclusionsPD-09, evidence grade C; design riskIs there a run-in or a washout longer than four weeks? Yes2×2×3Nothing yet
12MediumRun-in period before randomisationPD-10, evidence grade C; design riskIs there a run-in or a washout longer than four weeks? Yes2×2×3Nothing yet
12MediumDecentralised elementsPD-20, evidence grade C; design riskAre any visits done remotely or at home? Some visits2×2×3Nothing yet
12MediumNon-enrolling activated sitesS-01, evidence grade A; site riskSite new to research: 45% of sites3×2×2Study KPIs
12MediumSite type: enrolment rateS-07, evidence grade C; design and site riskWhat kind of sites will the study mostly use? Mostly independent sites and practices · Dedicated research centre: 18% of sites2×2×3Nothing yet
12MediumSites declining new studies for lack of capacityS-26, evidence grade C; site riskDedicated research centre: 18% of sites2×2×3Nothing yet
9MediumRestrictive eligibility criteria and protocol complexityEB-04, evidence grade B; design riskHow many non-essential exclusions does the protocol carry? Three or more3×3×1KRI: screen failure above the study's; QTL: ineligible patients randomised
9MediumEligibility criteria exclude patients (comorbidity, age, performance status, language)PB-02, evidence grade A; design riskHow many non-essential exclusions does the protocol carry? Three or more · Does the protocol exclude common comorbidities? Yes3×3×1KRI: screen failure above the study's; QTL: ineligible patients randomised
9MediumRestrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status)PD-01, evidence grade A; design riskHow many non-essential exclusions does the protocol carry? Three or more3×3×1KRI: screen failure above the study's; QTL: ineligible patients randomised
9MediumNumber of eligibility criteria and complexity growthPD-02, evidence grade B; design riskHow many non-essential exclusions does the protocol carry? Three or more3×3×1KRI: screen failure above the study's; KRI: important protocol deviations; QTL: ineligible patients randomised
6LowProcedural and visit burden (visits, blood draws, questionnaires)PD-03, evidence grade B; design riskHow heavy is the visit and procedure schedule? Heavier than typical2×3×1KRI: important protocol deviations; QTL: missing primary endpoint data; QTL: lost to follow-up or withdrew consent; QTL: stopped study treatment early
6LowProtocol amendmentsEB-18, evidence grade B; design riskHow settled is the protocol? Likely to change1×2×3Nothing yet
6LowPatient and public involvement in designEB-23, evidence grade B; design riskDid patients help design the protocol? No1×2×3Nothing yet
6LowRacial and ethnic under-representationPB-12, evidence grade A; country riskUnited States: Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies3×2×1KRI: enrolment against the diversity plan
6LowSubstantial protocol amendmentsPD-04, evidence grade B; design riskHow settled is the protocol? Likely to change1×2×3Nothing yet
6LowNo patient and public involvement in designPD-18, evidence grade A; design riskDid patients help design the protocol? No1×2×3Nothing yet
6LowNo upstream protocol feasibility reviewPD-21, evidence grade B; design riskHow settled is the protocol? Likely to change1×2×3Nothing yet
6LowThe US activates its first site quickly but scales its site fleet slowlyPM-03, evidence grade B; country riskUnited States: The first US site opens quickly, but the rest of the US sites open slowly3×2×1KRI: site activation overdue
6LowRegulator assessment backlogPOL-02, evidence grade A; country riskUnited Kingdom: The regulator's backlog of 2023 was cleared, but could recur1×2×3Nothing yet
6LowRegional regulatory transition friction (EU CTR and CTIS)POL-15, evidence grade A; country riskSpain: Applications go through the EU Clinical Trials Regulation and its portal · Poland: Applications go through the EU Clinical Trials Regulation and its portal3×2×1KRI: site activation overdue
6LowNew-to-sponsor siteS-05, evidence grade B; design and site riskHave most sites worked with the sponsor before? No, mostly new sites · Site new to research: 45% of sites3×2×1KRI: important protocol deviations
6LowProtocol amendments before and after activationS-14, evidence grade B; design riskHow settled is the protocol? Likely to change1×2×3Nothing yet
6LowFewer physicians willing to be investigatorsS-30, evidence grade C; site riskCommunity hospital: 8% of sites1×2×3Nothing yet
4LowTechnology burdenS-18, evidence grade B; design riskHow many vendors and systems will sites use? Many, or new to sites2×2×1KRI: data entry lag; KRI: queries open over 30 days
4LowProtocol complexity and site burdenS-24, evidence grade B; design and site riskHow heavy is the visit and procedure schedule? Heavier than typical · Community specialist practice: 7% of sites2×2×1KRI: important protocol deviations
3LowCoordinator turnoverS-09, evidence grade B; site riskRegional teaching hospital: 13% of sites · Community hospital: 8% of sites1×3×1KRI: data entry lag; KRI: queries open over 30 days
3LowSlow site payment and holdbacksS-17, evidence grade B; site riskCommunity specialist practice: 7% of sites1×1×3Nothing yet
2LowSite type: activation speedS-06, evidence grade A; design and site riskWhat kind of sites will the study mostly use? Mostly independent sites and practices · Academic medical centre: 8% of sites · Regional teaching hospital: 13% of sites1×2×1KRI: site activation overdue; Study KPIs
2LowSite capacity saturationS-11, evidence grade B; site riskAcademic medical centre: 8% of sites · Community specialist practice: 7% of sites1×2×1KRI: data entry lag
2LowStart-up: contracts and budgetsS-12, evidence grade A; site riskAcademic medical centre: 8% of sites · Regional teaching hospital: 13% of sites1×2×1KRI: site activation overdue; Study KPIs

How the scores are worked out

  • Likelihood. From the answer that switched the risk on: 3 if it cuts the recruitment rate to ×0.75 or below, 2 if it cuts it at all or changes screening or retention, 1 otherwise. From the risk's scope in the country: 3 if it touches all of the country's sites, 2 if some, 1 if only should an event recur. From the share of the study's sites whose profile carries the risk: 3 at 40% or more, 2 at 15% or more, 1 below.
  • Impact. Scores 3 if the risk threatens the result, the patients' safety or their rights; 1 if it mainly adds cost; 2 for everything else, which mostly delays recruitment.
  • Detectability. Scores 1 if a site-level KRI watches the risk every month, 2 if only a study-level KPI or QTL does, 3 if nothing does. A watched risk scores lower, so adding a KRI lowers the score.
  • Bands. High from 18, medium from 8, out of 27.
  • Method after TransCelerate RACT (2013); rules and cut-offs are epiClinical assumptions.